Data as of Aug 29
| 0.00 / 0.00%|
Aastrom Biosciences, Inc. is a regenerative medicine company which engages in the development of patient-specific, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases. The company's research and product development involves in the development of patient specific cell products for use in regenerative medicine. Its proprietary cell-manufacturing technology enables the manufacture of Ixmyelocel-T, a patient-specific, multicellular therapy, expanded from an adult's own bone marrow, and delivered directly to damaged tissues. Aastrom Biosciences was founded on March 24, 1989 and is headquartered in Ann Arbor, MI.
|Dominick C. Colangelo||President, CEO, Treasurer, Director & CAO|
|Daniel R. Orlando||Chief Operating Officer|
|Gerard J. Michel||Chief Financial Officer & VP-Corporate Development|
|Ross Tubo||Chief Scientific Officer|
|David Recker||Chief Medical Officer|